NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Evaluate ALN-2232 in Participants With Obesity

RecruitingPhase 1, Phase 2

Sponsor: Alnylam Pharmaceuticals

Conditions: Obesity

Interventions: ALN-2232, Placebo, Tirzepatide

Countries: Canada

The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

All Parts:

* Has a body mass index (BMI) of ≥30 kg/m\^2 and \<40 kg/m\^2
* Has a hemoglobin A1c (HbA1c) \<6.5%

Exclusion Criteria:

All Parts:

* Has any clinically significant concomitant disease, medical condition, or abnormal laboratory finding that could compromise participant safety or confound interpretation of study results
* Receiving therapies for chronic weight management or antidiabetic medications

Note: other protocol defined inclusion/exclusion criteria apply

Locations (1)

Mount Royal, Canada